Ironwood Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IRWD | 42C.SI | RX.V | 0950.HK | AKBA | I7G.F | |
|---|---|---|---|---|---|---|
| Market cap | 622.95M | 515.12M | 192.63M | 638.89M | 192.51M | 12.79B |
| P/E (TTM) | 4.9 | — | 20.2 | 5.4 | — | 25.1 |
| Forward P/E | 2.5 | 247.4 | 30.6 | 7.8 | -1.9 | — |
| Price/book | -3.9 | 33.6 | 4.2 | 0.3 | 7.6 | 2.7 |
| Dividend yield | — | — | 1.28% | 6.51% | — | 1.05% |
| 1-year change | +69.90% | +259.26% | +59.24% | −41.58% | −65.75% | +24.26% |
| Today | +7.71% | −3.09% | +1.78% | +0.93% | −4.28% | +2.04% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All IRWD news ›Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
“The Board would like to thank Tom for his steady leadership over the last 17 years. From the first approval and launch of LINZESS to the acquisition of VectivBio and progress of the apraglutide program, Tom has made an indelible mark on…
Ironwood Pharmaceuticals Names Tammi Gaskins as CEO, Effective January 2027 (IRWD)
On October 16, 2026, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced a leadership transition with the appointment of Tammi Gaskins, currently Chief Commercial Officer, as the new Chief Executive Officer effective January 1, 2027.…
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 7.4% – What’s Next?
Posted by Michael Walen on Oct 15th, 2026 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report)’s share price shot up 7.4% on Thursday. The company traded as high as $3.84 and last traded at $3.8650. Approximately 569,492 shares…
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Posted by Defense World Staff on Oct 13th, 2026 Check Out Our Latest Stock Report on Ironwood Pharmaceuticals Shares of Ironwood Pharmaceuticals stock opened at $3.76 on Tuesday. Ironwood Pharmaceuticals has a one year low of $1.41 and a…
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
Ironwood Pharmaceuticals' Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029. See why IRWD stock is a Buy now. - Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide,…
Ironwood Pharmaceuticals' future hinges on apraglutide amid generic threats to Linzess by 2029.
Ironwood Pharmaceuticals is rated Buy mainly due to its drug apraglutide, as its current cash flow from Linzess faces pressure from upcoming generic competition expected by 2029 and Medicare price cuts. Linzess revenues are largely…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net1
- gurufocus.com1
- mycarrollcountynews.com1
- pluang.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.